Skip to main content
ERAS
NASDAQ Life Sciences

Erasca Reports Strong Preliminary Cash Position of $341.8M at Year-End 2025

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$9
Mkt Cap
$2.783B
52W Low
$1.01
52W High
$10.42
52W Position info
791% above low
Off High info
14% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

ERAS has more than doubled off its 52-week low of $1.01 on elevated volume (1.9× avg).

Summary

Erasca, Inc. announced a preliminary cash, cash equivalents, and marketable securities balance of approximately $341.8 million as of December 31, 2025, signaling strong financial health for the biotech firm.


Key Events · Financing and Capital Events · ERAS

  • Preliminary Cash Position Reported

    Erasca, Inc. disclosed a preliminary unaudited cash, cash equivalents, and marketable securities balance of approximately $341.8 million as of December 31, 2025.

  • Unaudited Financial Information

    The reported financial information is based on preliminary unaudited estimates and is subject to completion of financial closing procedures and audit review.


Analysis · ERAS · Life Sciences

Erasca, a life sciences company, has reported a substantial preliminary cash, cash equivalents, and marketable securities balance of approximately $341.8 million as of December 31, 2025. This significant cash position provides a strong financial runway, which is critical for funding ongoing research and development in the capital-intensive biotech sector. While the figures are preliminary and unaudited, they indicate robust liquidity and financial stability, reducing immediate concerns about capital needs and supporting long-term strategic initiatives.

How filings like this one have moved

In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ERAS was trading at $9.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $1.01 to $10.42. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ERAS - Latest Insights

ERAS
Aug 24, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.11
Real-time Price: $14.95 info
Change: -$3.16 (-17%) info
Market Cap: $5.128B info
ERAS
Aug 24, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $18.11
Real-time Price: $14.95 info
Change: -$3.16 (-17%) info
Market Cap: $5.128B info
ERAS
Aug 11, 2026, 4:13 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $18.31
Real-time Price: $14.95 info
Change: -$3.36 (-18%) info
Market Cap: $5.128B info
ERAS
Aug 11, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $18.31
Real-time Price: $14.95 info
Change: -$3.36 (-18%) info
Market Cap: $5.128B info
ERAS
Aug 11, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.31
Real-time Price: $14.95 info
Change: -$3.36 (-18%) info
Market Cap: $5.128B info